Lead Product(s): INT301
Therapeutic Area: Immunology Product Name: INT301
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Intrommune Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2020
Based on this deal, Circuit Clinical will oversee the early clinical development of Intrommune’s lead drug, INT301, including a Phase 1b study planned for Q4 2020 and Q1 2021.